Oslo, Norway, March 6, 2024 - EXACT Therapeutics AS (Euronext Growth: EXTX), a
clinical stage precision health company utilizing Acoustic Cluster Therapy
(ACT®) across multiple therapeutic areas, today announced that it will be
presenting a poster on the ACTIVATE trial in patients with liver metastases of
colorectal cancer origin at the upcoming 2024 American Association for Cancer
Research (AACR) Annual Meeting, taking place April 5-10, 2024, in San Diego,
California. 

Dr. Amir Snapir, Chief Medical Officer of EXACT-Tx and Dr. Udai Banerji, the
principal investigator of the ACTIVATE trial will present the poster. Dr. Amir
Snapir comments: "We are excited to be at AACR to present details from the
promising ACTIVATE trial and supporting preclinical data. We are looking very
much forward to meeting other industry leaders and researchers here at AACR's
annual meeting." 

Details of the poster presentation are as follows: 

Abstract #: 6221

Title: First-in-Human Study of Acoustic Cluster Therapy (ACT®) consisting of
PS101 combined with Chemotherapy and insonation in Patients with Liver
Metastases of Colorectal Cancer Origin

Session date, time and location: April 9 at 1:30 p.m. - 5:00 p.m. in Poster
Section 36 

The poster will be made available in the Research Papers section of the
Company's website: https://exact-tx.com/publications-1-1 in parallel with the
Session. 

For more information, please contact: 
Per Walday 
CEO EXACT Therapeutics 
Email: per.walday@exact-tx.com 

About EXACT-Tx: 
EXACT-Tx is a clinical-stage Norwegian precision health company developing a
technology platform for targeted therapeutic enhancement - Acoustic Cluster
Therapy (ACT®). ACT® follows a unique approach to ultrasound-mediated, targeted
drug enhancement - with the potential to enable or significantly amplify the
clinical utility of a wide range of therapeutic agents across a multitude of
indications including within oncology (chemotherapy, immunotherapy) and brain
diseases. www.exact-tx.com 


About ACT® 
o ACT® is a proprietary formulation consisting of microbubbles and microdroplets
that are activated through the application of ultrasound with the consequent
increase in targeted delivery of a co-administered therapeutic agent. 
o ACT® is being tested in the clinic and has released positive interim data. It
is supported by a strong and broad preclinical package demonstrating therapeutic
enhancement in multiple oncology models (pancreatic, breast, colon, prostate) as
well as blood-brain barrier penetration. 
o Initial focus of the Company is oncology. The ACT® platform has potential
across many therapeutic areas (including CNS, immunotherapy) and product
classes. 

Forward looking statements: This announcement and any materials distributed in
connection with this announcement may contain certain forward-looking
statements. By their nature, forward-looking statements involve risk and
uncertainty because they reflect the Company's current expectations and
assumptions as to future events and circumstances that may not prove accurate. A
number of material factors could cause actual results and developments to differ
materially from those expressed or implied by this forward-looking statement.

This information is subject to the disclosure requirements pursuant to section
5-12 of the Norwegian Securities Trading Act.